RMR2 Antibody

What is the RRM2 antibody and what cellular processes does it target?

RRM2 antibody targets Ribonucleotide Reductase M2, one of two non-identical subunits of ribonucleotide reductase. This enzyme catalyzes the conversion of ribonucleotides to deoxyribonucleotides, a critical rate-limiting step in DNA synthesis and repair. RRM2 is particularly important in cell proliferation and DNA damage response pathways, making its antibody a valuable tool for investigating cell cycle regulation, DNA replication, and repair mechanisms . The antibody allows researchers to monitor RRM2 expression levels, which are often elevated in rapidly dividing cells, including many cancer types.

What types of RRM2 antibodies are available for research applications?

Several types of RRM2 antibodies are available for research, including rabbit monoclonal antibodies like the CPTC-RRM2-2 (RRID: AB_2617334) . These antibodies vary in their target recognition capabilities, with some designed to recognize specific peptide regions while others target recombinant full-length RRM2 protein. The selection of an appropriate antibody depends on the specific research application, including whether you need to detect denatured protein (for Western blotting), native protein (for immunoprecipitation), or fixed protein (for immunohistochemistry). Researchers should consider the antibody isotype (e.g., IgG) and species origin (e.g., rabbit) when designing experiments to avoid cross-reactivity issues.

How is RRM2 antibody validated for research use?

RRM2 antibodies undergo multiple validation methods to ensure specificity and sensitivity. For example, the CPTC-RRM2-2 antibody has been validated through:

• Indirect ELISA against both the specific peptide and full-length antigen, demonstrating high binding affinity

• Immuno-MRM (mass spectrometry-based immunoassay) in plasma samples, yielding positive results

• Immunohistochemistry evaluation by the Human Protein Atlas

This multi-platform validation approach ensures the antibody performs consistently across different experimental conditions and techniques. When selecting an RRM2 antibody for research, verification of validation data through resources like the Antibody Portal or manufacturer datasheets is essential to ensure experimental reproducibility.

What are the optimal conditions for using RRM2 antibody in Western blot analysis?

For optimal Western blot results with RRM2 antibody:

• Protein extraction: Use RIPA buffer supplemented with protease inhibitors to extract total protein from samples.

• Sample preparation: Denature proteins at 95°C for 5 minutes in Laemmli buffer containing β-mercaptoethanol.

• Gel electrophoresis: Separate 20-40 μg of protein on 10-12% SDS-PAGE gels.

• Transfer: Transfer proteins to PVDF membrane at 100V for 1 hour or 30V overnight at 4°C.

• Blocking: Block membrane with 5% non-fat dry milk in TBST for 1 hour at room temperature.

• Primary antibody: Dilute RRM2 antibody (typically 1:1000 to 1:2000) in blocking solution and incubate overnight at 4°C.

• Secondary antibody: Use appropriate HRP-conjugated secondary antibody (typically 1:5000 to 1:10000) for 1 hour at room temperature.

These conditions may require optimization based on your specific sample type and the particular RRM2 antibody you're using. The expected molecular weight of RRM2 is approximately 45 kDa, which should be verified when analyzing Western blot results.

How can I optimize immunoprecipitation protocols using RRM2 antibody?

For successful immunoprecipitation with RRM2 antibody:

• Cell lysis: Lyse cells in a non-denaturing buffer (e.g., NP-40 or CHAPS-based) with protease inhibitors.

• Pre-clearing: Pre-clear lysate with protein A/G beads to reduce non-specific binding.

• Antibody binding: Incubate 1-5 μg of RRM2 antibody with 500-1000 μg of pre-cleared lysate overnight at 4°C with gentle rotation.

• Bead capture: Add protein A/G beads and incubate for 2-4 hours at 4°C.

• Washing: Wash beads 4-5 times with cold lysis buffer.

• Elution: Elute bound proteins with SDS sample buffer for Western blot analysis.

A critical control is to perform a parallel immunoprecipitation with an isotype-matched control antibody to identify non-specific interactions. Based on experimental evidence with similar antibodies, the optimal antibody-to-protein ratio typically falls between 1:100 and 1:200 by mass for RRM2 immunoprecipitation.

What methods can be used to detect RRM2 in clinical samples using antibody-based approaches?

Several antibody-based methods are effective for detecting RRM2 in clinical samples:

• Immunohistochemistry (IHC): Allows visualization of RRM2 expression patterns in tissue sections, though the CPTC-RRM2-2 antibody showed negative results in HPA evaluation .

• Immuno-MRM: A mass spectrometry-based approach that has shown positive results with the CPTC-RRM2-2 antibody in plasma samples .

• Enzyme-Linked Immunosorbent Assay (ELISA): Both indirect and sandwich ELISA formats can be used, with the CPTC-RRM2-2 antibody demonstrating high binding in indirect ELISA .

• Multiplexed immunoassays: Allow simultaneous detection of RRM2 alongside other DNA damage response markers.

For clinical samples, consideration of pre-analytical variables (fixation method, processing time) is crucial for accurate results. Validation against established biomarkers and correlation with clinical outcomes are necessary steps when developing RRM2-based diagnostic approaches.

How do I interpret contradictory RRM2 antibody results between different detection methods?

When facing contradictory results between detection methods:

• Consider epitope accessibility: The CPTC-RRM2-2 antibody showed high binding in ELISA but negative results in IHC , suggesting potential epitope masking in fixed tissues.

• Evaluate protein conformation: Some antibodies recognize only specific conformations (native vs. denatured).

• Assess cross-reactivity: Verify specificity against recombinant RRM2 and related proteins (e.g., RRM1).

• Compare detection limits: Different methods have varying sensitivity thresholds.

• Validate with multiple antibodies: Use antibodies targeting different RRM2 epitopes.

When interpreting contradictory results, prioritize data from methods with appropriate positive and negative controls. For instance, the positive immuno-MRM results for CPTC-RRM2-2 might be more reliable for plasma samples than negative IHC results for tissue samples , as these methods differ in sample processing and epitope presentation.

What are common causes of false positive and false negative results when using RRM2 antibody?

Common causes of false results include:

False Positives:

• Cross-reactivity with related proteins (particularly RRM1)

• Non-specific binding of secondary antibody

• Endogenous peroxidase activity in immunohistochemistry

• Sample contamination with proliferating cells expressing high RRM2 levels

False Negatives:

• Epitope masking due to fixation or processing (particularly in formalin-fixed tissues)

• Insufficient antigen retrieval

• Antibody degradation or denaturation

• Expression levels below detection threshold

To minimize false results, always include appropriate positive controls (e.g., proliferating cell lines known to express RRM2) and negative controls (e.g., samples with RRM2 knockdown or tissues known to have low expression).

How can I troubleshoot weak or non-specific signals when using RRM2 antibody in immunoassays?

For weak signals:

• Increase antibody concentration (step-wise, e.g., 2-fold)

• Extend incubation time (overnight at 4°C instead of 1-2 hours)

• Optimize antigen retrieval for fixed samples

• Use signal amplification systems (e.g., tyramide signal amplification)

• Switch to more sensitive detection methods (e.g., from chromogenic to fluorescent)

For non-specific signals:

• Increase blocking concentration (5-10% instead of 1-3%)

• Use alternative blocking agents (BSA, normal serum, casein)

• Increase washing stringency (higher salt concentration, longer washes)

• Pre-adsorb antibody with potential cross-reactants

• Titrate antibody to determine optimal concentration

The evidence from CPTC-RRM2-2 characterization suggests high binding specificity in ELISA , indicating that optimization of blocking and washing conditions may be particularly important when troubleshooting this antibody in other applications.

How can RRM2 antibody be used to study DNA damage response pathways?

RRM2 antibody can be employed to study DNA damage response through:

• Temporal analysis: Monitor RRM2 expression changes following DNA damage induction (UV, ionizing radiation, chemotherapy agents) using Western blot or immunofluorescence.

• Spatial analysis: Examine RRM2 colocalization with DNA damage markers (γH2AX, 53BP1) using confocal microscopy.

• Pathway interaction: Use RRM2 antibody in co-immunoprecipitation to identify interaction partners in the DNA damage response pathway.

• Chromatin association: Perform chromatin immunoprecipitation (ChIP) to assess RRM2 recruitment to damage sites.

As RRM2 is part of the DNA Damage Response (DDR) Pathway panel , combining its detection with other DDR components provides comprehensive pathway analysis. Researchers can develop experimental time courses to track RRM2 dynamics during different phases of the damage response, from initial detection through repair completion.

What approaches can be used to study RRM2 post-translational modifications using specific antibodies?

To study RRM2 post-translational modifications:

• Phospho-specific antibodies: Use antibodies that recognize specific phosphorylation sites on RRM2 (e.g., Thr33, Ser20) to monitor cell cycle-dependent regulation.

• Ubiquitination analysis: Combine RRM2 immunoprecipitation with ubiquitin Western blotting to assess protein degradation regulation.

• Acetylation detection: Use pan-acetyl-lysine antibodies following RRM2 immunoprecipitation.

• Mass spectrometry validation: Confirm antibody-detected modifications through mass spectrometric analysis of immunoprecipitated RRM2.

When studying post-translational modifications, validation is crucial. This can be accomplished by comparing wild-type cells with those expressing RRM2 mutants where the modified residue has been replaced (e.g., serine to alanine to prevent phosphorylation), providing a negative control for modification-specific antibodies.

How can RRM2 antibody be integrated into multiplexed imaging approaches for studying cell cycle dynamics?

For multiplexed imaging of RRM2 in cell cycle studies:

• Sequential immunofluorescence: Use fluorophore-conjugated RRM2 antibody alongside cell cycle markers (cyclin B1, Ki67, PCNA).

• Cyclic immunofluorescence (CycIF): Strip and re-probe the same sample with multiple antibodies including RRM2.

• Mass cytometry (CyTOF): Label RRM2 antibody with metal isotopes for high-dimensional analysis.

• Imaging mass cytometry: Combine CyTOF with imaging for spatial resolution of RRM2 and cell cycle markers.

These approaches allow correlation of RRM2 expression patterns with specific cell cycle phases and cellular compartments. Quantitative image analysis can then reveal relationships between RRM2 levels, localization, and cell cycle position, particularly important given RRM2's role in DNA synthesis during S phase.

How are computational approaches being integrated with antibody-based detection of RRM2?

Computational approaches enhancing RRM2 antibody research include:

• Epitope prediction: In silico methods predict optimal epitopes for generating highly specific RRM2 antibodies.

• Structural modeling: Computational models predict antibody-antigen interactions, similar to the RFdiffusion approach used for other antibodies .

• Image analysis algorithms: Automated quantification of RRM2 immunostaining in tissue microarrays correlates expression with clinical outcomes.

• Network analysis: Integration of RRM2 antibody-derived expression data with pathway information to identify functional relationships.

Recent advances in antibody design using RFdiffusion networks suggest similar approaches could be applied to generate improved RRM2-targeting antibodies with enhanced specificity and affinity. These computational methods also help identify potential cross-reactivity issues before experimental validation.

What are the current developments in antibody engineering technologies applied to RRM2 research?

Recent developments in antibody engineering relevant to RRM2 research include:

• De novo design: Computational methods like RFdiffusion are enabling the design of antibodies with atomic-level precision , which could be applied to create highly specific RRM2 antibodies.

• Single-domain antibodies: Development of nanobodies and VHH fragments against RRM2 for improved tissue penetration.

• Bispecific formats: Engineering antibodies that simultaneously target RRM2 and interacting proteins for functional studies.

• Recombinant expression systems: Optimized production of consistent RRM2 antibodies in mammalian cells to overcome batch variation.

The emerging technologies in de novo antibody design are particularly promising, as they could enable the creation of RRM2 antibodies that target specific conformational states or post-translational modifications with unprecedented precision. These approaches may overcome current limitations in RRM2 detection across different experimental platforms.

How can RRM2 antibodies be used in conjunction with emerging single-cell technologies?

RRM2 antibodies can be integrated with single-cell technologies through:

• Single-cell Western blotting: Detection of RRM2 protein levels in individual cells to assess heterogeneity.

• Mass cytometry: Metal-labeled RRM2 antibodies for high-dimensional protein profiling at single-cell resolution.

• CITE-seq: Oligonucleotide-tagged RRM2 antibodies for simultaneous protein and transcriptome analysis.

• 4i multiplexed imaging: Iterative immunofluorescence including RRM2 antibody for spatial proteomics.

These approaches allow researchers to correlate RRM2 protein expression with transcriptomic data, providing insights into post-transcriptional regulation mechanisms. Single-cell technologies are particularly valuable for studying RRM2 in heterogeneous samples such as tumors, where different cell populations may show distinct expression patterns related to proliferation status and therapy response.

What are the best practices for using RRM2 antibody in cancer research studies?

For optimal use of RRM2 antibody in cancer research:

• Patient sample selection: Include matched normal and tumor tissues from the same patient when possible.

• Cell line validation: Verify RRM2 antibody specificity in cancer cell lines with known RRM2 expression levels.

• Therapy response monitoring: Establish baseline RRM2 levels before treatment and track changes during therapy.

• Prognostic value assessment: Correlate RRM2 expression with clinical outcomes using standardized scoring systems.

The inclusion of RRM2 in DNA Damage Response pathway panels makes it particularly valuable for studies on cancer therapeutics targeting DNA replication and repair. Researchers should consider combining RRM2 detection with markers of proliferation (Ki67) and DNA damage (γH2AX) for comprehensive tumor characterization.

How can conformational specificity of RRM2 antibodies impact experimental outcomes?

The conformational specificity of RRM2 antibodies significantly impacts experimental results:

• Native vs. denatured recognition: Some RRM2 antibodies may only recognize the protein in its native conformation, as suggested by differential results between assay platforms for the CPTC-RRM2-2 antibody .

• Post-translational modification accessibility: Conformational changes may expose or hide modification sites.

• Protein-protein interaction interfaces: Antibodies targeting interaction surfaces may disrupt biological functions in functional assays.

• Fixation effects: Chemical fixatives can alter protein conformation, affecting epitope recognition in immunohistochemistry.

Researchers should characterize whether their RRM2 antibody recognizes linear or conformational epitopes by comparing results in denaturing (Western blot) versus non-denaturing (native PAGE, flow cytometry) conditions. This characterization is essential for selecting appropriate applications and interpreting results accurately.